Dr Mary Gospodarowicz
O. Harold Warwick Prize recipient in 2016
Dr Mary Gospodarowicz is a leading radiation oncologist whose devotion to advancing cancer control is recognized worldwide. Her drive to optimize treatment for genitourinary cancers and lymphomas has changed how they are managed, improving patient outcomes.
Dr Gospodarowicz has demonstrated exceptional dedication and leadership in radiation oncology for over 30 years. Early on, she recognized the potential long-term risks of radiation therapy, which motivated her to define the best ways to integrate radiation into cancer management. In the 1990s, Dr Gospodarowicz’ pioneering research on testicular cancer changed the paradigm for how it should be treated. This research led to a new approach that limited radiation therapy after surgery in low-risk patients to minimize harmful side effects. Her leadership in clinical trials is reflected in a landmark study that found an increased risk of certain cancers in testicular cancer survivors after radiation therapy. In addition to these accomplishments, Dr Gospodarowicz has been a champion for achieving global consensus on cancer staging. She served as an editor of the 7th edition of the TNM Classification of Malignant Tumours (2011), which has been cited over 11,000 times.
Dr Gospodarowicz’ service to the scientific community has been outstanding. Notably, her involvement in committees of the Canadian Cancer Trials Group (CCTG; formerly the NCIC Clinical Trials Group) has positioned her to guide cancer research that truly makes a difference. She has also been instrumental in establishing a global task force to advocate for access to radiation therapy worldwide, especially in low- or middle-income countries. Dr Gospodarowicz is known to be a caring physician and an exemplary ambassador for cancer research.
Cancer affects all Canadians
Nearly 1 in 2 Canadians is expected to be diagnosed with cancer in their lifetime.